222 related articles for article (PubMed ID: 30689765)
1. Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.
Wang MH; Friton JJ; Raffals LE; Leighton JA; Pasha SF; Picco MF; Cushing KC; Monroe K; Nix BD; Newberry RD; Faubion WA
J Crohns Colitis; 2019 Aug; 13(8):1036-1043. PubMed ID: 30689765
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
3. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.
Lew D; Yoon SM; Yan X; Robbins L; Haritunians T; Liu Z; Li D; McGovern DP
World J Gastroenterol; 2017 Oct; 23(40):7265-7273. PubMed ID: 29142473
[TBL] [Abstract][Full Text] [Related]
4. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
Polo Y La Borda J; Campos J; Sanz J; Andréu JL; Mulero J; Sánchez A
Int J Rheum Dis; 2019 Aug; 22(8):1529-1537. PubMed ID: 31119895
[TBL] [Abstract][Full Text] [Related]
5. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?
Maldonado-Pérez MB; Castro-Laria L; Caunedo-Álvarez A; Montoya-García MJ; Giner-García M; Argüelles-Arias F; Romero-Gómez M; Vázquez-Gámez MÁ
J Clin Densitom; 2019; 22(2):195-202. PubMed ID: 30205986
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P; Salvador-Martín S; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Sánchez-Hernández JG; Rodríguez A; Bossacoma F; Balboa MJ; Salcedo E; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2023 Aug; 194():106859. PubMed ID: 37473877
[TBL] [Abstract][Full Text] [Related]
7. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.
Yoon SM; Haritunians T; Chhina S; Liu Z; Yang S; Landers C; Li D; Ye BD; Shih D; Vasiliauskas EA; Ippoliti A; Rabizadeh S; Targan SR; Melmed GY; McGovern DPB
Inflamm Bowel Dis; 2017 Aug; 23(8):1382-1393. PubMed ID: 28590340
[TBL] [Abstract][Full Text] [Related]
8. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
Bangma A; Voskuil MD; Uniken Venema WTC; Brugge H; Hu S; Lanting P; Franke L; Dijkstra G; Festen EAM; Weersma RK
Aliment Pharmacol Ther; 2020 Jun; 51(11):1105-1115. PubMed ID: 32363635
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
10. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.
Qiu Y; Zheng Z; Liu G; Zhao X; He A
United European Gastroenterol J; 2019 Nov; 7(9):1198-1214. PubMed ID: 31700633
[TBL] [Abstract][Full Text] [Related]
11. Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.
Borren NZ; Luther J; Colizzo FP; Garber JG; Khalili H; Ananthakrishnan AN
J Crohns Colitis; 2019 Aug; 13(8):990-995. PubMed ID: 30888405
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort.
Tremelling M; Waller S; Bredin F; Greenfield S; Parkes M
Inflamm Bowel Dis; 2006 Mar; 12(3):178-84. PubMed ID: 16534418
[TBL] [Abstract][Full Text] [Related]
13. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
14. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
15. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
Sridhar S; Maltz RM; Boyle B; Kim SC
Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
[TBL] [Abstract][Full Text] [Related]
16. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
[TBL] [Abstract][Full Text] [Related]
17. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
Schultheiss JPD; Brand EC; Lamers E; van den Berg WCM; van Schaik FDM; Oldenburg B; Fidder HH
Aliment Pharmacol Ther; 2019 Aug; 50(4):386-396. PubMed ID: 31310690
[TBL] [Abstract][Full Text] [Related]
18. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
19. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Rasmussen BK; Avlund S; Olesen TB; Hoffmann HJ; Thomsen MK; Thomsen VØ; Frydenberg M; Nexø BA; Sode J; Vogel U; Andersen V
Pharmacogenomics J; 2014 Dec; 14(6):526-34. PubMed ID: 24776844
[TBL] [Abstract][Full Text] [Related]
20. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
Vedak P; Kroshinsky D; St John J; Xavier RJ; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2016 Mar; 43(6):697-704. PubMed ID: 26806281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
